Lv71
3655 积分 2021-07-08 加入
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
21天前
已完结
肠促胰素类减重药物临床应用专家共识（2025版）
24天前
已完结
肺部影像报告和数据系统2022版更新解读
24天前
已完结
Is Weight Loss-Induced Muscle Mass Loss Clinically Relevant?
29天前
已完结
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
1个月前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
1个月前
已完结
Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II
1个月前
已完结
IcoSema and the evolution of fixed-ratio insulin-GLP-1 receptor agonist therapies
1个月前
已完结
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial
1个月前
已完结
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial
1个月前
已完结
皖公网安备34019202002308
